Med Discovery is a Swiss biopharmaceutical company dedicated to the discovery and the development of highly specific treatments for uro-genital cancers. Our strategy is to develop protein drugs based on the optimization of natural proteins involved in the regulation of biological pathways.
David Deperthes, Ph.D. ? CEO and President
Founder and CEO of Med Discovery, Dr. Deperthes obtained his Ph.D. in Molecular and Cellular Biology from Laval University in Canada. Discoverer of a new prostate cancer marker, the kallikrein hK2, with Prof. Rolland R. Tremblay, he specialized in the development of new molecules for tumor targeting with J.P. Mach at the ISREC in Lausanne.
Christoph Kündig, Ph.D. ? Chief Scientific Officer
Dr. Kündig obtained his Ph.D. in life sciences at the Swiss Institute of Technology in Zurich, Switzerland. He joined Professor Marc Ouellette's laboratory at Laval University (Québec, Canada) in 1994 as post-doctoral fellow. He worked on drug target discovery and the molecular biology of Leishmaniosis.